# Celltrion Starts Lilly Production at Branchburg and Plans to More Than Double Capacity

The New Jersey acquisition brought an experienced workforce and continuing Lilly production into Celltrion. After December's closing and February's operating start, the company enlarged its planned expansion in March while preparing its own product transfers.

Canonical: https://kgcf.dsmlholdings.com/insights/celltrion-branchburg-local-production/
Published: 2026-10-08
Modified: 2026-10-31
Author: [DSML Holdings LLC](https://www.dsmlholdings.com/)

Company: Celltrion / Celltrion USA
Event: 2025-09-19
The Q1 filing dates the acquisition agreement to 19 September 2025; the 23 September shareholder letter says 20 September local time. Acquisition completed on 31 December 2025.

## Reported Metrics

- Facility-company acquisition consideration: USD 330m. USD330 million acquisition agreement dated 19 September 2025 in Celltrion's Q1 2026 filing. [Source 1](https://kind.krx.co.kr/external/2026/05/15/003225/20260515007366/11013.htm)

Celltrion completed the Branchburg acquisition on 31 December 2025 and reported Lilly production across the site's lines in February 2026. Its team also began validating Celltrion products. In March, the company increased its planned capacity addition to 75,000 litres, which would take the existing 66,000-litre site to 141,000 litres.

The Korean company bought an operating factory with an experienced workforce and continuing customer production. Lilly remained a customer while Celltrion prepared a second role for the site: manufacturing its own medicines closer to their American market. The first months joined a completed handover, continuing customer work and a larger expansion decision.

The acquisition agreement stated USD330 million, and a separate Lilly contract scheduled USD473 million of manufacturing supply. Customer work gave the transferred operation a defined purpose while Celltrion invested in its next uses. The longer project combines local manufacture of Celltrion products with services for other drug developers, coordinated through Celltrion BioSolutions.

## Celltrion Chose an Operating Factory in New Jersey

Celltrion had announced its selection as preferred bidder in July 2025. By September, it had agreed to acquire Lilly's drug-substance manufacturing facility in Branchburg through its US subsidiary. The campus included production, logistics, technical-support and operating buildings, with vacant land available for expansion. It offered an existing manufacturing organisation at a time when Celltrion wanted a US production base.

The September Korean release put the purchase at USD 330 million and outlined a much larger investment programme: approximately KRW 700 billion including acquisition and initial operating funds, followed by at least another KRW 700 billion for expansion. Those announced plans separated buying the factory from financing its operation and enlarging it.

Celltrion had several tasks to complete before it could operate the factory as its own. The September agreement would be followed by merger review and a transfer of ownership, with both companies aiming for a year-end close. Choosing an existing campus shortened the route to a US manufacturing organisation, but its adaptation to Celltrion products would continue beyond the purchase.

3. [Celltrion / original September shareholder letter, staffing and validation timetable](https://www.celltrion.com/en-us/company/notice/4164)
5. [Celltrion / original Korean acquisition release, purchase and additional investment plans](https://www.celltrion.com/ko-kr/company/media-center/press-release/4169)
1. [Celltrion / Q1 2026 regulatory filing, major contracts](https://kind.krx.co.kr/external/2026/05/15/003225/20260515007366/11013.htm)

## Lilly's Manufacturing Team Was Part of What Celltrion Bought

The original Korean announcement included a response from Edgardo Hernandez, Lilly's executive vice-president and president of manufacturing operations. He described Branchburg as a Lilly production base over seventeen years and acknowledged the local team's experience and work supplying medicines. Celltrion's own account said the agreement included full employment succession.

That workforce gave the acquisition a different starting point from a greenfield project requiring recruitment and training before production could begin. The companies said they would cooperate through the handover until the factory had its new operating arrangements. The retained staff were therefore part of the means of continuing customer supply, alongside the physical equipment.

The commercial logic was continuity, not simply extra litres. Celltrion could preserve know-how around products already made at the site while preparing a different set of medicines for future manufacture. The inherited organisation also remained responsible for dependable production during the change of ownership.

5. [Celltrion / original Korean acquisition release, purchase and additional investment plans](https://www.celltrion.com/ko-kr/company/media-center/press-release/4169)
3. [Celltrion / original September shareholder letter, staffing and validation timetable](https://www.celltrion.com/en-us/company/notice/4164)

## The December Closing Came With a Separate USD 473 Million Order

On 2 January 2026, Celltrion announced that transfer had completed on 31 December. It said the September purchase agreement had been followed by merger reviews in Ireland and the United States during October and November. The Q1 filing subsequently records acquisition of all equity in ImClone Systems LLC and its renaming as Celltrion Branchburg LLC.

The same filing dates the separate Lilly manufacturing agreement to 31 December 2025. Its legal term runs through December 2029, with actual supply planned from Q2 2026 to Q1 2029. The USD 473 million describes contracted supply over that interval. The January announcement presented that customer work as a way to support the newly acquired operation while Celltrion prepared its own products.

The Q1 accounts also report KRW643.087 billion of business-combination consideration, without a full bridge to the USD330 million acquisition headline. The continuing Lilly work is a production contract, with costs to meet as well as supply to deliver. It gives the plant an initial workload while the new owner develops its next operating role.

4. [Celltrion / January closing release, supply contract and proposed capacity expansion](https://www.celltrion.com/ko-kr/company/media-center/press-release/4380)
1. [Celltrion / Q1 2026 regulatory filing, major contracts](https://kind.krx.co.kr/external/2026/05/15/003225/20260515007366/11013.htm)

## February Brought Lilly Production Across the Lines

Following the year-end transfer, Celltrion inspected the whole site and completed full-scale operating preparations by the end of January. In its 25 February letter, the company reported that Lilly CMO production had begun across all lines that month. The handover had become an active manufacturing operation under its new owner.

At the same time, Celltrion began validation for its own products. Its September estimate had allowed twelve to eighteen months for that work. The inherited Lilly processes and the Celltrion transfers therefore progressed on different schedules: experienced staff could continue making the customer's medicines while the new owner's products went through the preparation required for manufacture at the site.

2. [Celltrion / February 2026 operating status and issuer tariff-risk strategy](https://www.celltrion.com/en-us/company/notice/4561)
3. [Celltrion / original September shareholder letter, staffing and validation timetable](https://www.celltrion.com/en-us/company/notice/4164)
4. [Celltrion / January closing release, supply contract and proposed capacity expansion](https://www.celltrion.com/ko-kr/company/media-center/press-release/4380)

## US Inventory Was the Immediate Tariff Response

Seo Jung-jin had set out Celltrion's tariff-response plan in May 2025, according to the company's September acquisition account. Moving about two years of inventory to the United States and extending local CMO arrangements came first. Branchburg supplied the longer-term manufacturing element of that strategy.

The February letter described the same sequence: US-positioned stock supported near-term supply while local production was prepared for the years ahead. Management presented it as protection from tariff uncertainty. Its usefulness rests on the actual products transferred and qualified for the US site, not simply possession of an American address.

2. [Celltrion / February 2026 operating status and issuer tariff-risk strategy](https://www.celltrion.com/en-us/company/notice/4561)
3. [Celltrion / original September shareholder letter, staffing and validation timetable](https://www.celltrion.com/en-us/company/notice/4164)
5. [Celltrion / original Korean acquisition release, purchase and additional investment plans](https://www.celltrion.com/ko-kr/company/media-center/press-release/4169)

## March Brought a Larger Branchburg Plan and a Wider CMO Push

In January, Celltrion had proposed another KRW700 billion to expand Branchburg from 66,000 to 132,000 litres. On 24 March, it enlarged the planned addition from 66,000 to 75,000 litres, taking the future site target to 141,000 litres. The existing 66,000 litres remained the operating base; the new figure described what the expansion would provide.

The change formed part of a wider manufacturing programme staged from 2026 to 2030, including new Songdo facilities. Celltrion wanted more capacity both for its expanding medicine portfolio and for external customers. The US site had a particular role in serving the American market, while Korean facilities supported the wider supply network.

A week earlier, on 17 March, the company had announced a further global pharmaceutical CMO order for supply during 2027-2029. That agreement concerned the wider company, without assigning its production to Branchburg. It nevertheless showed the service business growing alongside the new US operating base. Celltrion BioSolutions was building global sales and project-management capability for that work.

The organisation set out in January gave Celltrion and Celltrion USA responsibility for infrastructure and investment, with BioSolutions managing customers and projects. Branchburg was becoming part of that manufacturing network through a retained team, a continuing Lilly contract and preparations for Celltrion's own medicines. The proposed 75,000-litre addition remained a construction project alongside the operating 66,000-litre factory.

4. [Celltrion / January closing release, supply contract and proposed capacity expansion](https://www.celltrion.com/ko-kr/company/media-center/press-release/4380)
6. [Celltrion / March capacity decision raises Branchburg addition to 75,000 litres](https://www.celltrion.com/ko-kr/company/media-center/press-release/4669)
7. [Celltrion / separate company-wide CMO order and BioSolutions operating role](https://www.celltrion.com/en-us/company/media-center/press-release/4639)

Preserving Lilly production gives Celltrion a stronger start than an empty factory. The longer-term result still depends on completing its own transfers and securing enough qualified work for the proposed expansion; neither follows automatically from the acquisition closing.


### Primary Sources

1. [Celltrion / Q1 2026 regulatory filing, major contracts](https://kind.krx.co.kr/external/2026/05/15/003225/20260515007366/11013.htm) (2026-05-15)

2. [Celltrion / February 2026 operating status and issuer tariff-risk strategy](https://www.celltrion.com/en-us/company/notice/4561) (2026-02-25)

3. [Celltrion / original September shareholder letter, staffing and validation timetable](https://www.celltrion.com/en-us/company/notice/4164) (2025-09-23)

4. [Celltrion / January closing release, supply contract and proposed capacity expansion](https://www.celltrion.com/ko-kr/company/media-center/press-release/4380) (2026-01-02)

5. [Celltrion / original Korean acquisition release, purchase and additional investment plans](https://www.celltrion.com/ko-kr/company/media-center/press-release/4169) (2025-09-23)

6. [Celltrion / March capacity decision raises Branchburg addition to 75,000 litres](https://www.celltrion.com/ko-kr/company/media-center/press-release/4669) (2026-03-24)

7. [Celltrion / separate company-wide CMO order and BioSolutions operating role](https://www.celltrion.com/en-us/company/media-center/press-release/4639) (2026-03-17)
